InMode: A Measured Long — Don’t Hope, Trade the Facts

Hook / Thesis

InMode is a classic event-driven trade dressed up as a healthcare recovery story. The company builds minimally invasive and non-invasive aesthetic devices and sits on a large cash balance with no debt. That combination made it an attractive target for Steel Partners earlier this year, which proposed an $18 per share take‑private offer. The bid frames a clear upside near‑term and gives active investors a reference price — but it is not a guaranteed deal, and the business is still fighting weaker procedure demand and recurring guidance downgrades.

My thesis: hope alone - i.e., expecting demand to rebound and management to execute a turnaround without clear evidence - is not an effective investment strategy. Neither is despair. The current setup offers a defined asymmetric opportunity if you are willing to bet on either bumps to procedure demand or continued activism that forces a higher takeout/kicker. I want to own the trade with strict risk controls rather than hold the company on faith.

What InMode Does and Why the Market Should Care

InMode Ltd. designs, manufactures and sells energy‑based aesthetic devices used in med‑spas and clinics for non‑invasive and minimally invasive procedures — hair reduction, skin rejuvenation, body contouring, cellulite treatment, and related indications. These procedures are part of a long‑run secular trend: global demand for minimally invasive aesthetic treatments is growing, and industry reports project multi‑billion dollar market expansion over the next decade. That structural tailwind matters because InMode's product set sits at the intersection of two profitable dynamics: high device ASPs and recurring consumable/upgrade revenue for clinics that buy their platforms.

Key fundamentals and the market snapshot

Two numbers jump off the page: the cash hoard (reported by the activist at ~$532.3M) and the company’s ability to turn out meaningful free cash flow ($61.8M). Those facts create two natural valuation anchors: a balance‑sheet floor and an earnings/cash flow multiple. At a market cap of roughly $820M and enterprise value near $751.7M, InMode is not priced like a high‑growth software flier — it is priced as a capital‑light medical hardware company with earnings and cash generation. EV/EBITDA of about 12.8x is reasonable, and with no debt the optionality of shareholder action (dividends, buybacks, strategic sale) is real.

Why the market has punished the shares

Execution and demand have been uneven. Management has cut guidance multiple times, and procedure volume in the near term has been soft. Technically, the stock is below its 10/20/50 day moving averages and the 9‑day EMA ($14.42) and 21‑day EMA ($14.62) are above price; RSI is ~33.6, signaling weak momentum but not extreme capitulation. Short interest is meaningful (~2.36M shares most recently), and short volume has been a significant portion of daily turnover on many sessions — a mixed signal that increases volatility.

Valuation framing — realistic not heroic

Valuation comes down to two lenses: intrinsic business value and event value. Intrinsically, using trailing free cash flow of $61.8M and an enterprise value of ~$751.7M implies EV/FCF ≈ 12.2x. On an earnings basis, implied P/E is in the low‑ to mid‑teens. Those multiples are conservative for a profitable med‑tech name with strong margins (ROA ~17.5%, ROE ~20.1%), but they reflect current demand weakness and repeated guidance cuts. Event value comes from the Steel Partners proposal: a public bid at $18 is a visible floor for upside if a deal or competing bids emerge.

Catalysts

• Steel Partners activism - continued engagement, a firmed offer, or a competing bid that pushes price toward $18.
• Evidence of procedure recovery - sequential revenue or procedure growth acceleration in upcoming quarterly updates or regionally positive comps.
• Operational moves - clearer capital allocation: buybacks, special dividends, or M&A that re‑rate the stock.
• New product adoption - traction for recently launched platforms (IgniteRF, OptimasMAX) translating into device placements and consumable revenue.
• Sector tailwinds - broader growth in energy‑based aesthetic devices and med‑spa expansion in North America.

Trade plan (actionable)

Direction: Long

Entry price: $14.25

Target price: $18.00

Stop loss: $12.50

Horizon: mid term (45 trading days) — This is a time window that captures near‑term catalysts: potential activist developments, quarterly results or incremental operational announcements, and any quick bounce in procedure demand. If the stock reaches target early, take profits; if it fails and breaches the stop, cut losses quickly.

Rationale: Entry at $14.25 gives you a decent proximity to the current price while respecting intraday slippage. The $18 target is not arbitrary: it matches the reported unsolicited proposal and represents a clear technical/catalyst level. The $12.50 stop sits below the 52‑week low ($12.72) and protects downside in case demand deterioration worsens or activism stalls.

Position sizing and risk posture

This is a high‑risk trade idea. Use a position size that limits the portfolio risk from this single trade to low single-digit percentages. The play is partially event driven — if activism accelerates or the company reports better than feared results, upside can be quick; if not, the stock can languish or gap lower on weak earnings or guidance cuts.

Counterarguments & alternative scenarios

• Steel Partners’ $18 proposal may not be binding. The activist can walk away or fail to secure a deal, leaving the stock where fundamentals dictate.
• Procedure volumes could remain depressed; repeated guidance cuts suggest underlying demand is cyclical and vulnerable to macro pressure.
• Management may misallocate its cash hoard or delay shareholder returns, keeping the discount to intrinsic value persistent.

Risks (detailed)

• Demand risk: A slow recovery in elective aesthetic procedures is the primary business risk. Continued weakness would compress revenue and margins and could force further guidance reductions.
• Execution risk: New platforms must convert into placements and recurring consumables. Failure to gain traction would hurt growth and investor confidence.
• Event risk: The activist bid may not materialize into a transaction. An unsuccessful activism campaign could lead to prolonged volatility and no takeout premium.
• Valuation/market risk: While multiples are reasonable, the stock could derate if macro sentiment punishes small cap med‑tech names or if peers reset valuation lower.
• Liquidity and volatility: Average volumes are modest (two‑week avg ~488k), and short interest plus high short volume on many sessions increases the chance of abrupt price moves and wide intraday spreads.

What would change my view

I would become more bullish if management articulates a credible demand recovery with concrete metrics — sequential device placements, stronger consumable attach rates, or improved guidance — or if activism yields concrete shareholder return actions (scheduled buybacks or a firmed sale process). I would become more bearish if another quarter produces a guidance cut, margins deteriorate, or the company announces sub‑par uptake for its new platforms.

Bottom line

INMD is not a “set‑and‑forget” long for investors who need predictability. It is a traded idea: asymmetric, catalyst‑driven and binary to some degree. With a current price of $14.27, a free cash flow generator, and a visible $18 bid on the tape, the setup favors a disciplined, mid‑term long with a tight stop. This trade respects both the balance sheet and the operational realities — hope is not a strategy, but neither is surrender.

Trade plan recap: Long INMD at $14.25; target $18.00; stop $12.50; horizon mid term (45 trading days). Stick to the stop and reassess on key quarterly data or activist updates.